FACA Committee Purpose & Justification The information in this plan was imported from the Federal Advisory Committee Act (FACA) database and transformed into StratML Part 1, Strategic Plan, format. Fiscal Year:2011 Committee Type: Scientific Technical Program Advisory Board Anti Infective Drugs Advisory Committee HHS 0a1e033b-5563-44c7-aaa8-abced7fe8f88 [ Location : (http://stratml.fido.gov/dick/HHSFACA109.xml) ][ Federated Name : (urn:www.hhs.gov:agency:32:committee:109:) ][ Agency Name : (Department of Health and Human Services) ][ Agency Acronym : (HHS) ][ Agency Domain : (www.hhs.gov) ] [ Agency Web Site : (http://www.hhs.gov/) ][ Committee Name : (Anti Infective Drugs Advisory Committee) ][ Committee Type : (Scientific Technical Program Advisory Board) ][ Committee Web Site : (http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/default.htm) ][ Goal? : (no) ][ Vision? : (no) ][ Mission? : (yes) ] Department of Health and Human Services http://www.hhs.gov/ http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/default.htm Not Available 78d4c946-cfc5-4b4f-b238-3d1061ea24f8 FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Anti-Infective Drugs Advisory Committee supports FDA's strategic priorities by reviewing and evaluating available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and make appropriate recommendations to the Commissioner of Food and Drugs. This supports the development of safe and effective new medical technologies, and advances the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection of public health. e03f8581-f210-404a-9dfb-f65a80c555e3 Not Available e3102b97-0297-4551-bb9c-b9919bee5c3b 43e72a74-837d-4f4e-adc4-ee1d15ceea64 42e274b8-285d-4f13-b684-423a77380273 2010-10-01 2011-09-30 2013-07-09 http://explore.data.gov/resource/datasets/c5i3-bb9j Gannon (J.) Dick gannon_dick@yahoo.com